This afternoon (February 19), the joint prevention and control mechanism of the State Council held a press conference. At the meeting, Wu Liangyou, deputy director of the disease control bureau of the National Health Commission, said that recently, with the approval of the joint prevention and control mechanism of the State Council, the National Health Commission has begun to deploy sequential immunization.
Previously, the target population over 18 years old who has been vaccinated with inactivated vaccine of Sinopharm Zhongsheng Beijing company, Beijing Kexing company, Sinopharm Zhongsheng Wuhan company or adenovirus vector vaccine of Tianjin Cansino Biologics Inc(688185) company for 6 months can be immunized with one dose of primary homologous booster vaccine, that is, with the original vaccine. After the implementation of the sequential booster immunization strategy, the target population who has completed the whole process of vaccination with the above three inactivated vaccines can also choose the recombinant protein vaccine of zhifeilongke horse or Cansino Biologics Inc(688185) adenovirus vector vaccine for sequential booster immunization. For the target population, one of homologous booster immunization and sequential booster immunization can be selected. In addition, the joint prevention and control mechanism of the State Council also approved the homologous enhanced immunization of covid-19 virus inactivated vaccine of Shenzhen Kangtai company and the Institute of biology of the medical college. Whether homologous enhancement or sequential enhancement, it should be implemented in people over 18 years old who have completed the whole process of vaccination for 6 months.
The research data show that both homologous booster immunization and sequential booster immunization can further improve the immune effect. It is hoped that people who meet the vaccination conditions can take the initiative to vaccinate and vaccinate as soon as possible, so as to add weight to health and refuel for epidemic prevention.
China has deployed vaccine R & D units to carry out R & D of Omicron mutant vaccine
The enhanced immunization of covid-19 vaccine in China has an inhibitory effect on the breakthrough infection of Omicron strain
